Journal Article Epublish
PubMed: 40076685 DOI: 10.3390/ijms26052062
Comprehensive Assessment of Neuropathy and Metabolic Parameters in Type 1 Diabetic Patients with or Without Using Continuous Glucose Sensors.
Int J Mol Sci 26(5)
Authors: Barbara Bordács, Ákos Várkonyi, Zsuzsanna Valkusz, Szabolcs Nyiraty, Anikó Pósa, Adrienn Menyhárt, Csaba Lengyel, Péter Kempler, Krisztina Kupai, Tamás Várkonyi
Affiliations
- Department of Internal Medicine, Albert Szent-Györgyi Medical School, University of Szeged, 6725 Szeged, Hungary.
- Faculty of Dentistry, University of Szeged, 6720 Szeged, Hungary.
- Department of Oncology and Internal Medicine, Faculty of Medicine, Semmelweis University, 1083 Budapest, Hungary.
Abstract
The present study was conducted in type 1 diabetic (T1DM) patients to evaluate the metabolic and glycemic control as well as the manifestations of neuropathy. The impact of continuous glucose monitoring (CGM) on the measured parameters was also analyzed. A total of 61 T1DM patients (age: 42.5 ± 1.8 years, DM duration: 22.8 ± 1.6 years, mean ± SE) participated in the study. In total, 24 patients had CGM sensors and 37 did not. Cardiovascular autonomic neuropathy was assessed using cardiovascular reflex tests. Peripheral sensory function was evaluated by a Neurometer and calibrated tuning fork on the upper and lower limbs. Metabolic status was characterized by the determination of triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, and glycated haemoglobin (HbA). A positive correlation was found between HbA and triglyceride levels (r = 0.28, < 0.05). CGM users and non-users differed in triglyceride (0.9 ± 0.1 vs. 1.24 ± 0.12 mmol/L, < 0.05), HDL cholesterol (1.7 ± 0.1 vs. 1.4 ± 0.1 < 0.05 mmol/L), and HbA (7.5 ± 0.2 vs. 8.3 ± 0.3%, < 0.05) levels as well. Significant differences were found for the Valsalva ratio, Neurometer, and calibrated tuning fork results between CGM users and non-users. This study found a significant correlation between HbA and triglyceride levels in T1DM. CGM use resulted in improved metabolic parameters and less autonomic and sensory nerve damage. As a novel finding, CGM is presumed to prevent both micro-, and macrovascular complications and, by this way, potentially reducing mortality rates.
MeSH
Diabetes Mellitus, Lipoproteins, Cholesterol, Triglycerides, Continuous Glucose Monitoring